- Home
- LUCD vs SKYE Comparison
LUCD vs SKYE Comparison
Compare LUCD & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUCD
- SKYE
- Stock Information
- Founded
- LUCD 2018
- SKYE 2012
- Country
- LUCD United States
- SKYE United States
- Employees
- LUCD N/A
- SKYE N/A
- Industry
- LUCD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- LUCD Health Care
- SKYE Health Care
- Exchange
- LUCD Nasdaq
- SKYE Nasdaq
- Market Cap
- LUCD 112.5M
- SKYE 115.9M
- IPO Year
- LUCD 2021
- SKYE N/A
- Fundamental
- Price
- LUCD $1.11
- SKYE $3.91
- Analyst Decision
- LUCD Strong Buy
- SKYE Buy
- Analyst Count
- LUCD 4
- SKYE 6
- Target Price
- LUCD $3.94
- SKYE $16.60
- AVG Volume (30 Days)
- LUCD 1.5M
- SKYE 1.1M
- Earning Date
- LUCD 08-11-2025
- SKYE 08-08-2025
- Dividend Yield
- LUCD N/A
- SKYE N/A
- EPS Growth
- LUCD N/A
- SKYE N/A
- EPS
- LUCD N/A
- SKYE N/A
- Revenue
- LUCD $4,173,000.00
- SKYE N/A
- Revenue This Year
- LUCD $49.70
- SKYE N/A
- Revenue Next Year
- LUCD $198.20
- SKYE N/A
- P/E Ratio
- LUCD N/A
- SKYE N/A
- Revenue Growth
- LUCD 39.89
- SKYE N/A
- 52 Week Low
- LUCD $0.72
- SKYE $1.14
- 52 Week High
- LUCD $1.80
- SKYE $7.47
- Technical
- Relative Strength Index (RSI)
- LUCD 44.54
- SKYE 54.94
- Support Level
- LUCD $1.08
- SKYE $3.46
- Resistance Level
- LUCD $1.14
- SKYE $4.40
- Average True Range (ATR)
- LUCD 0.07
- SKYE 0.37
- MACD
- LUCD 0.00
- SKYE -0.07
- Stochastic Oscillator
- LUCD 41.03
- SKYE 45.92
About LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.